WO2015017675A3 - Methods and compounds useful in conditions related to repeat expansion - Google Patents

Methods and compounds useful in conditions related to repeat expansion Download PDF

Info

Publication number
WO2015017675A3
WO2015017675A3 PCT/US2014/049197 US2014049197W WO2015017675A3 WO 2015017675 A3 WO2015017675 A3 WO 2015017675A3 US 2014049197 W US2014049197 W US 2014049197W WO 2015017675 A3 WO2015017675 A3 WO 2015017675A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds useful
conditions related
repeat expansion
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/049197
Other languages
French (fr)
Other versions
WO2015017675A2 (en
Inventor
Thazha P. Prakash
Jiaxin Hu
Jing Liu
Dongbo YU
David Corey
Eric E. Swayze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
Isis Pharmaceuticals Inc
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Isis Pharmaceuticals Inc, University of Texas at Austin filed Critical University of Texas System
Priority to EP14832900.6A priority Critical patent/EP3027617B1/en
Priority to US14/908,429 priority patent/US10435430B2/en
Publication of WO2015017675A2 publication Critical patent/WO2015017675A2/en
Publication of WO2015017675A3 publication Critical patent/WO2015017675A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Described are compounds and methods useful for the treatment and investigation of diseases and disorders associated with expanded repeat-containing RNA molecules. In certain embodiments, compounds and methods useful for the modulation of ATXN-3 pre-mRNA are described. In certain embodiments, compounds and methods useful for the modulation of ATN-1 mRNA are described.
PCT/US2014/049197 2013-07-31 2014-07-31 Methods and compounds useful in conditions related to repeat expansion Ceased WO2015017675A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP14832900.6A EP3027617B1 (en) 2013-07-31 2014-07-31 Methods and compounds useful in conditions related to repeat expansion
US14/908,429 US10435430B2 (en) 2013-07-31 2014-07-31 Methods and compounds useful in conditions related to repeat expansion

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361860823P 2013-07-31 2013-07-31
US61/860,823 2013-07-31
US201462019820P 2014-07-01 2014-07-01
US62/019,820 2014-07-01

Publications (2)

Publication Number Publication Date
WO2015017675A2 WO2015017675A2 (en) 2015-02-05
WO2015017675A3 true WO2015017675A3 (en) 2015-04-02

Family

ID=52432576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/049197 Ceased WO2015017675A2 (en) 2013-07-31 2014-07-31 Methods and compounds useful in conditions related to repeat expansion

Country Status (3)

Country Link
US (1) US10435430B2 (en)
EP (1) EP3027617B1 (en)
WO (1) WO2015017675A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282155B (en) 2008-12-02 2017-06-09 日本波涛生命科学公司 The synthetic method of the nucleic acid of phosphorus atoms modification
RU2612521C2 (en) 2009-07-06 2017-03-09 Онтории, Инк. Novel prodrugs of nucleic acids and their application methods
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan Asymmetric auxiliary group
CN103796657B (en) 2011-07-19 2017-07-11 波涛生命科学有限公司 Methods of Synthesizing Functionalized Nucleic Acids
PL2872485T3 (en) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymmetric auxiliary group
BR112016011770B1 (en) * 2013-11-27 2022-10-25 Sigma-Aldrich Co. Llc METHOD AND KIT FOR MICRORNA ISOLATION FROM A BIOLOGICAL SAMPLE
BR112016016400A2 (en) 2014-01-16 2017-10-03 Wave Life Sciences Ltd COMPOSITIONS OF CHIRALLY CONTROLLED OLIGONUCLEOTIDES, THEIR USE, THEIR PHARMACEUTICAL COMPOSITION, AND METHODS
EP4285912A3 (en) 2015-09-25 2024-07-10 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
WO2018051762A1 (en) * 2016-09-14 2018-03-22 レナセラピューティクス株式会社 Antisense oligonucleotide with reduced side effects
JOP20190104A1 (en) * 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
EP4663758A3 (en) 2018-05-09 2026-04-29 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn3 expression
EP3965777A4 (en) * 2019-05-06 2024-08-07 The Children's Hospital of Philadelphia MICRORNA SITE-BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS
CN113950529A (en) 2019-06-06 2022-01-18 豪夫迈·罗氏有限公司 Antisense oligonucleotides targeting ATXN3
KR20220133925A (en) 2020-01-31 2022-10-05 가부시키가이샤산와카가쿠켄큐쇼 Antisense oligonucleotides of ATN1
AR124229A1 (en) 2020-12-03 2023-03-01 Hoffmann La Roche ANTISENSE OLIGONUCLOTIDES ACTING ON ATXN3
US20230060373A1 (en) 2020-12-03 2023-03-02 Hoffmann-La Roche Inc. Antisense Oligonucleotides Targeting ATXN3
JP2024536132A (en) 2021-09-29 2024-10-04 エフ． ホフマン－ラ ロシュ アーゲー RNA editing method
EP4594498A2 (en) * 2022-09-28 2025-08-06 Atalanta Therapeutics, Inc. Compositions and methods for treatment of spinocerebellar ataxias
WO2025252669A1 (en) 2024-06-03 2025-12-11 Evotec International Gmbh Modified oligonucleotides for reducing atxn3 expression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253583A1 (en) * 2004-09-27 2009-10-08 Med Biogene Inc. Hematological Cancer Profiling System
WO2013033223A1 (en) * 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
US20130059902A1 (en) * 2010-02-08 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
WO2013096679A1 (en) * 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (en) 1985-01-08 1987-04-03 Pasteur Institut NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
EP0366685B1 (en) 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
JPH0874B2 (en) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド Nuclease-resistant, pyrimidine-modified oligonucleotides that detect and modulate gene expression
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
JPH08504559A (en) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド Motor system with individually controlled redundant windings
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
JP4236812B2 (en) 1997-09-12 2009-03-11 エクシコン エ／エス Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
EP1991677A2 (en) 2006-01-26 2008-11-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
SI2049664T1 (en) 2006-08-11 2012-04-30 Prosensa Technologies Bv Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders
EP2560001B1 (en) 2006-09-21 2016-04-13 University of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
CA2732343C (en) 2008-07-29 2017-05-09 The Board Of Regents Of The University Of Texas System Selective inhibition of polyglutamine protein expression
DK2356129T3 (en) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituted alpha-L bicyclic nucleosides
EP2447274B1 (en) * 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
US20120059045A1 (en) 2008-10-24 2012-03-08 Isis Pharmaceuticals, Inc. Methods of using oligomeric compounds comprising 2'-substituted nucleosides
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
WO2011097614A1 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Mehods and compositions useful in diseases or conditions related to repeat expansion
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US9156873B2 (en) * 2010-04-28 2015-10-13 Isis Pharmaceuticals, Inc. Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (en) 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
EP2595663A4 (en) * 2010-07-19 2014-03-05 Isis Pharmaceuticals Inc MODULATION OF THE EXPRESSION OF MYOTONIC DYSTROPHIC PROTEIN KINASE (DMPK)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253583A1 (en) * 2004-09-27 2009-10-08 Med Biogene Inc. Hematological Cancer Profiling System
US20130059902A1 (en) * 2010-02-08 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
WO2013033223A1 (en) * 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
WO2013096679A1 (en) * 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
US10435430B2 (en) 2019-10-08
EP3027617C0 (en) 2026-02-18
EP3027617B1 (en) 2026-02-18
EP3027617A4 (en) 2017-04-12
EP3027617A2 (en) 2016-06-08
US20160159846A1 (en) 2016-06-09
WO2015017675A2 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
WO2015017675A3 (en) Methods and compounds useful in conditions related to repeat expansion
MX2024010175A (en) ANTIBODY MOLECULES AGAINST APRIL AND THEIR USES.
MX2016007541A (en) Modified nucleic acid molecules and uses thereof.
WO2014113089A3 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
PL3527068T3 (en) METHODS AND COMPOSITIONS TO INCREASE THE EFFECTIVENESS OF TARGETED GENE MODIFICATION USING GENE REPAIR IN WHICH INTERMEDIATE OLIGONUCLEOTIDE
EP3095460A4 (en) Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
MX2016006271A (en) SOLID FORMS OF ACID {[5- (3-CHLOROPHENYL) -3-HYDROXIPIRIDIN-2-CARB ONIL] AMINO} ACETIC, COMPOSITIONS, AND USES OF THE SAME.
WO2012159051A3 (en) Chemically modified graphene
WO2015010135A3 (en) Compositions for modulating tau expression
PL3604536T3 (en) RNA-MODULATING OLIGONUCLEOTIDES WITH IMPROVED PROPERTIES FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
LT3004166T (en) METHODS FOR IMPROVING SPECIFIC IMMUNOTHERAPY IN THE CONTEXT OF ALLERGEN BY INTRODUCING THE IL-4R INHIBITOR
CO6940374A2 (en) Compositions, uses and methods for the treatment of disorders and metabolic diseases
PL2920363T3 (en) The papermaking system, the method of producing the papermaking system and its use
MX2015012401A (en) Compositions and methods of altering cholesterol levels.
Bercher Some properties of generalized Fisher information in the context of nonextensive thermostatistics
PT2838539T (en) ESTROGENIC DERIVATIVES FOR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS.
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
EP3054935A4 (en) Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
EP3078379A4 (en) Drug for the treatment of cholesterol accumulation disorders, and screening method for same
SG11201508680VA (en) New carbodiimides having terminal urea and/or urethane groups, methods for producing said carbodiimides, and use of said carbodiimides
EP3110974A4 (en) Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
MX2016012206A (en) T7 rna polymerase variants with expanded substrate range and enhanced transcriptional yield.
EP3040351A4 (en) Modified acrylic block copolymer, method for producing same, and intended use of same
EP3035992A4 (en) Compositions, methods and systems for the treatment of cutaneous disorders
PL2819974T3 (en) FERTILIZER, ITS USE AND METHOD OF PRODUCTION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832900

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014832900

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832900

Country of ref document: EP

Kind code of ref document: A2

WWG Wipo information: grant in national office

Ref document number: 2014832900

Country of ref document: EP